SLCO4C1

Solute carrier organic anion transporter family member 4C1 · Q6ZQN7 · SLCO4C1 on Sugi Atlas →

2,575 patent compounds predicted against SLCO4C1, 2,202 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sarmentogenin (SCHEMBL1230965)	0.65	2/20
Gitoxigenin (SCHEMBL644087)	0.62	2/20
Gitoxigenin (SCHEMBL3302691)	0.62	2/20
Gitoxigenin (SCHEMBL3302694)	0.62	2/20
Gitoxigenin (SCHEMBL8417147)	0.62	2/20
SCHEMBL8830484	0.54	2/20
SCHEMBL8830696	0.54	2/20
Ethyl Acetate (SCHEMBL2958120)	0.49	2/20
Ethyl Acetate (SCHEMBL2960997)	0.48	2/20
SCHEMBL7277851	0.42	2/20
SCHEMBL7393179	0.42	2/20
Digitoxin (SCHEMBL20940)	1.00	1/20
Digoxigenin (SCHEMBL21105)	1.00	1/20
Levothyroxine (SCHEMBL23098)	1.00	1/20
Thyroxine (SCHEMBL26147)	1.00	1/20
Dextrothyroxine (SCHEMBL61194)	1.00	1/20
Digitoxin (SCHEMBL2321116)	1.00	1/20
Digitoxigenin Bisdigitoxoside (SCHEMBL2514789)	1.00	1/20
Digitoxigenin Bisdigitoxoside (SCHEMBL2514793)	1.00	1/20
Levothyroxine (SCHEMBL3286699)	1.00	1/20

Clinical trials — most relevant to SLCO4C1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use	PHASE4	COMPLETED
Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects	PHASE4	COMPLETED
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®	PHASE1/PHASE2	COMPLETED
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis	PHASE2	UNKNOWN
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	PHASE1	COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC	PHASE1	COMPLETED
A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults	PHASE1	COMPLETED
Statin Therapy to Improve Medication Adherence	PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
The Furosemide Stress Test, Electrolytes Response and Renal Index in Critically Ill Patients	nan	COMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Placental Transfer of Tenofovir	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLCO4C1 binder may also engage these)

Protein	Name	Similarity
Q5RFF0	—	1.000	Q5RFF0 →
Q8BGD4	—	0.997	Q8BGD4 →
Q71MB6	—	0.995	Q71MB6 →
Q9JJL3	—	0.994	Q9JJL3 →
Q9QZX8	—	0.992	Q9QZX8 →
Q99J94	—	0.992	Q99J94 →
Q9UIG8	—	0.990	Q9UIG8 →
Q9QYE2	—	0.989	Q9QYE2 →
SLCO1B3	Solute carrier organic anion transporter family member 1B3	0.989	landscape →
P46720	—	0.989	P46720 →
Q9NYB5	—	0.987	Q9NYB5 →
Q9ERB5	—	0.987	Q9ERB5 →
Q9QXZ6	—	0.987	Q9QXZ6 →
Q91YY5	—	0.986	Q91YY5 →
Q8HYW2	—	0.986	Q8HYW2 →
Q8R3L5	—	0.986	Q8R3L5 →
Q9EP96	—	0.986	Q9EP96 →
O35913	—	0.986	O35913 →
P70502	—	0.985	P70502 →
G3V0H7	—	0.985	G3V0H7 →
Q9EPZ7	—	0.985	Q9EPZ7 →
Q99N02	—	0.984	Q99N02 →
SLCO1B1	Solute carrier organic anion transporter family member 1B1	0.983	landscape →
F5H094	—	0.983	F5H094 →
SLCO1A2	Solute carrier organic anion transporter family member 1A2	0.982	landscape →
O88397	—	0.981	O88397 →
Q86UG4	—	0.981	Q86UG4 →
Q9VVH9	—	0.981	Q9VVH9 →
Q9GMU6	—	0.981	Q9GMU6 →
Q09630	—	0.978	Q09630 →